Edward Nash
Stock Analyst at Canaccord Genuity
(3.47)
# 906
Out of 5,148 analysts
80
Total ratings
46.58%
Success rate
6.76%
Average return
Main Sectors:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KNSA Kiniksa Pharmaceuticals International, | Initiates: Buy | $62 | $46.00 | +34.78% | 1 | Feb 19, 2026 | |
| CORT Corcept Therapeutics | Maintains: Buy | $99 → $100 | $35.97 | +178.01% | 12 | Jan 23, 2026 | |
| VTYX Ventyx Biosciences | Downgrades: Hold | $16 → $14 | $13.98 | +0.14% | 8 | Jan 8, 2026 | |
| VERU Veru Inc. | Initiates: Buy | $25 | $2.62 | +854.20% | 1 | Dec 18, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $526 → $587 | $435.62 | +34.75% | 12 | Nov 13, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $106 → $107 | $33.34 | +220.94% | 2 | Nov 12, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $28 | $5.72 | +389.51% | 2 | Oct 2, 2025 | |
| IVA Inventiva | Maintains: Buy | $20 | $6.29 | +217.97% | 3 | Sep 30, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $62 | $30.00 | +106.67% | 3 | Sep 17, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $29.53 | +59.16% | 10 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $1.36 | +561.76% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $1.27 | +214.96% | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $70.92 | +25.50% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.02 | +684.31% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $3.14 | +441.40% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $3.34 | -40.12% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $0.62 | +29,049.80% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $52 | $10.33 | +403.39% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $23.02 | +256.21% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $10.50 | +357.14% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $5.06 | +12,745.85% | 1 | Nov 8, 2017 |
Kiniksa Pharmaceuticals International,
Feb 19, 2026
Initiates: Buy
Price Target: $62
Current: $46.00
Upside: +34.78%
Corcept Therapeutics
Jan 23, 2026
Maintains: Buy
Price Target: $99 → $100
Current: $35.97
Upside: +178.01%
Ventyx Biosciences
Jan 8, 2026
Downgrades: Hold
Price Target: $16 → $14
Current: $13.98
Upside: +0.14%
Veru Inc.
Dec 18, 2025
Initiates: Buy
Price Target: $25
Current: $2.62
Upside: +854.20%
Madrigal Pharmaceuticals
Nov 13, 2025
Maintains: Buy
Price Target: $526 → $587
Current: $435.62
Upside: +34.75%
Viking Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $106 → $107
Current: $33.34
Upside: +220.94%
Sagimet Biosciences
Oct 2, 2025
Maintains: Buy
Price Target: $28
Current: $5.72
Upside: +389.51%
Inventiva
Sep 30, 2025
Maintains: Buy
Price Target: $20
Current: $6.29
Upside: +217.97%
Celldex Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $62
Current: $30.00
Upside: +106.67%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $29.53
Upside: +59.16%
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $1.36
Upside: +561.76%
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.27
Upside: +214.96%
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $70.92
Upside: +25.50%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.02
Upside: +684.31%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $3.14
Upside: +441.40%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $3.34
Upside: -40.12%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $0.62
Upside: +29,049.80%
Aug 5, 2022
Downgrades: Hold
Price Target: $52
Current: $10.33
Upside: +403.39%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $23.02
Upside: +256.21%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $10.50
Upside: +357.14%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $5.06
Upside: +12,745.85%